Amy Abernethy appointed FDA acting chief information officer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Amy Abernethy, FDA principal deputy commissioner, was appointed the agency’s acting chief information officer and lead the Office of Information Management and Technology in addition to her other duties.

Craig Taylor has been acting as FDA’s CIO in addition to serving as the Chief Information Security Officer. He will continue to serve as the Chief Information Security Officer.

Abernethy came to FDA earlier this year, leaving her position as chief medical officer, chief scientific officer and senior vice president of oncology at Flatiron Health (The Cancer Letter, Dec. 17, 2018).

As acting CIO, Abernethy will “bring a new perspective to the FDA’s information technology programs and priorities,” agency officials said in an announcement of Abernethy’s appointment. “She was one of the pioneers in bioinformatics, and her career has focused on how to use software and data to simultaneously accelerate clinical research while informing personalized healthcare and scientific discovery.

“As science and medicine continue to evolve, the FDA’s priorities and regulatory science programs will continue to require the efficient and effective application of new technology; including the latest advancements in artificial intelligence, machine learning, data analytics, scientific and high-performance computing, and other technologies to support the specific mission areas of each Center and Office.”

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login